Press Release | ERDERA Clinical Trial Call

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA has opened its Clinical Trial Call 2026, a funding opportunity for multinational early-phase interventional clinical trials in rare diseases.

The call supports sponsor-led Phase I, Phase I/II and Phase II trials of medicinal products designed to generate robust clinical evidence, strengthen regulatory readiness and improve trial feasibility across countries.

Up to €30 million is dedicated to the call, with individual project budgets broadly expected in the range of €1 million to €5 million.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Source

ERDERA

Author

ERDERA

You might also be interested in

ERDERA 2026 Open Session

From individual cases to new treatment pathways: ERDERA Open Session focuses on ultra-rare diseases

ERDERA marked the close of its second year with an Open Session on ultra-rare diseases, bringing together European, regulatory and scientific perspectives on how innovation can reach patients.
ERDERA JTc 2027

ERDERA pre-announces 2027 Joint Transnational Call on recently identified rare diseases

The Joint Transnational Call is expected to open on 1 December 2026, with an information webinar planned for 14 December.
Training online

Information Webinar – ERDERA Joint Transnational Call 2027

December 14 @ 3:00 pm - 4:00 pm
This information webinar on the 2027 Joint Transnational Call for Proposals is scheduled for 14 December 2026.
Cover of the 16-country rare disease policy assessment, October 2026.

Reckoning With the Rare Disease Landscape. A 16 Country Policy Landscape Assessment across the Life Course.

The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.

ERDERA Search